205 related articles for article (PubMed ID: 33645373)
21. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
22. Current and Emerging Treatments for Waldenström Macroglobulinemia.
Grimont CN; Castillo Almeida NE; Gertz MA
Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
[TBL] [Abstract][Full Text] [Related]
23. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
24. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
Dimopoulos MA; Kastritis E; Ghobrial IM
Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
[TBL] [Abstract][Full Text] [Related]
25. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
26. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.
Sarosiek S; Castillo JJ
Drugs; 2024 Jan; 84(1):17-25. PubMed ID: 38055179
[TBL] [Abstract][Full Text] [Related]
27. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
[TBL] [Abstract][Full Text] [Related]
28. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
29. Toward personalized treatment in Waldenström macroglobulinemia.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):365-370. PubMed ID: 29222280
[TBL] [Abstract][Full Text] [Related]
30. Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754469
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal Antibodies for Waldenström Macroglobulinemia.
Dominguez A; Kastritis E; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):841-852. PubMed ID: 30190022
[TBL] [Abstract][Full Text] [Related]
32. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
33. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia.
Treon SP; Hunter ZR; Castillo JJ; Merlini G
Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
[TBL] [Abstract][Full Text] [Related]
35. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
36. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
37. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
38. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
39. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Dimopoulos MA; Terpos E; Kastritis E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
